Key result
In a Taiwanese registry of patients hospitalized for acute decompensated HFrEF, the 1-year all-cause mortality rate was 15.9% and the 1-year heart failure re-hospitalization rate was 38.5%.
Observational (n=1,509)
Yes
The TSOC-HFrEF registry highlights a high 1-year mortality and re-hospitalization rate among acute decompensated HFrEF patients in Taiwan, alongside suboptimal use of guideline-directed medical therapy.
High one-year mortality and rehospitalization in TSOC-HFrEF underscore care gaps; leaves open whether better GDMT implementation improves Asian HFrEF outcomes.
BACKGROUND: Heart failure (HF) is a global health problem. The Taiwan Society of Cardiology-Heart Failure with reduced Ejection Fraction (TSOC-HFrEF) registry was a multicenter, observational survey of patients admitted with HFrEF in Taiwan. The aim of this study was to report the one-year outcome in this large-cohort of hospitalized patients presenting with acute decompensated HFrEF. METHODS: Patients hospitalized for acute HFrEF were recruited in 21 hospitals in Taiwan. A total of 1509 patients were enrolled into the registry by the end of October 2014. Clinical status, readmission rates and dispensed medications were collected and analyzed 1 year after patient index hospitalization. RESULTS: Our study indicated that re-hospitalization rates after HFrEF were 31.9% and 38.5% at 6 and 12 months after index hospitalization, respectively. Of these patients, 9.7% of them were readmitted more than once. At 6 and 12 months after hospital discharge, all-cause mortality rates were 9.5% and 15.9%, respectively, and cardiovascular mortality rates were 6.8% and 10.5%, respectively. Twenty-three patients (1.5%) underwent heart transplantation. During a follow-up period of 1 year, 46.4% of patients were free from mortality, HF re-hospitalization, left ventricular assist device use and heart transplantation. At the conclusion of follow-up, 57.5% of patients were prescribed either with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; also, 66.3% were prescribed with beta-blockers and 40.8% were prescribed with mineralocorticoid receptor antagonists. CONCLUSIONS: The TSOC-HFrEF registry showed evidence of suboptimal practice of guideline-directed medical therapy and high HF re-hospitalization rate in Taiwan. The one-year mortality rate of the TSOC-HFrEF registry remained high. Ultimately, our data indicated a need for further improvement in HF care.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2017) conducted an observational in Acute decompensated systolic heart failure (HFrEF) (n=1,509). Acute decompensated HFrEF was evaluated on 1-year all-cause mortality. In a Taiwanese registry of patients hospitalized for acute decompensated HFrEF, the 1-year all-cause mortality rate was 15.9% and the 1-year heart failure re-hospitalization rate was 38.5%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: